Dr. Daniel George, M.D.
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 215
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Duke University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Urology Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
- Duke Regional Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 215
- Services billed
- 836
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 333 | 171 |
| Established patient office or other outpatient visit, 30-39 minutes | 76 | 57 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 91 |
| Prednisone Other prescribers in Durham, NC | 77 |
| Nubeqa (darolutamide) | 65 |
| Abiraterone Acetate | 53 |
| Cabometyx (cabozantinib s-malate) | 51 |
| Xtandi (enzalutamide) | 34 |
| Prochlorperazine Maleate Other prescribers in Durham, NC | 29 |
| Lenvima (lenvatinib mesylate) | 27 |
| Eliquis (apixaban) Other prescribers in Durham, NC | 24 |
| Inlyta (axitinib) | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 66 payments worth $157,241 in total to this clinician.
| Pfizer Inc. | $47,535 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $35,004 |
| AstraZeneca UK Limited | $21,230 |
| E.r. Squibb & Sons, L.l.c. | $18,407 |
| Novartis Pharmaceuticals Corporation | $11,941 |
| AstraZeneca Pharmaceuticals LP | $11,257 |
| Sumitomo Pharma America, Inc. | $7,880 |
| Eisai Inc. | $3,070 |
| Consulting Fee | $152,453 |
|---|---|
| Travel and Lodging | $3,695 |
| Food and Beverage | $1,093 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Jun 3, 2025 | Consulting Fee Nubeqa · Oncology | $18,000 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee XTANDI · ONCOLOGY | $17,520 |
| Pfizer Inc. May 15, 2025 | Consulting Fee XTANDI · ONCOLOGY | $17,420 |
| E.r. Squibb & Sons, L.l.c. Oct 16, 2025 | Consulting Fee | $16,578 |
| Pfizer Inc. Dec 17, 2025 | Consulting Fee | $11,500 |
| Sumitomo Pharma America, Inc. Aug 28, 2025 | Consulting Fee ORGOVYX · PROSTATE CANCER | $7,848 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 30, 2025 | Consulting Fee Nubeqa · Oncology | $6,300 |
| Novartis Pharmaceuticals Corporation Jul 1, 2025 | Consulting Fee | $4,250 |
| AstraZeneca UK Limited Jul 7, 2025 | Consulting Fee LYNPARZA · Oncology | $3,425 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $3,400 |
All 48 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Dec 29, 2025 | Consulting Fee Lenvima · Oncology | $2,910 |
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee Truqap · Oncology Company’s descriptionResearch Related Service | $2,460 |
| Pfizer Inc. Dec 17, 2025 | Consulting Fee | $11,500 |
| AstraZeneca Pharmaceuticals LP Dec 17, 2025 | Consulting Fee Truqap · Oncology | $3,280 |
| AstraZeneca UK Limited Dec 15, 2025 | Consulting Fee | $1,370 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 30, 2025 | Consulting Fee Nubeqa · Oncology | $6,300 |
| E.r. Squibb & Sons, L.l.c. Oct 30, 2025 | Travel and Lodging travel to BOSTON, MA | $137 |
| AstraZeneca UK Limited Oct 24, 2025 | Consulting Fee Truqap · Oncology | $2,050 |
| E.r. Squibb & Sons, L.l.c. Oct 16, 2025 | Consulting Fee | $16,578 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 29, 2025 | Consulting Fee Nubeqa · Oncology | $900 |
| AstraZeneca UK Limited Sep 15, 2025 | Consulting Fee | $2,055 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $757 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| Sumitomo Pharma America, Inc. Aug 28, 2025 | Consulting Fee ORGOVYX · PROSTATE CANCER | $7,848 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 21, 2025 | Consulting Fee | $1,800 |
| AstraZeneca UK Limited Aug 12, 2025 | Consulting Fee | $2,055 |
| AstraZeneca UK Limited Jul 7, 2025 | Consulting Fee LYNPARZA · Oncology | $3,425 |
| Novartis Pharmaceuticals Corporation Jul 1, 2025 | Consulting Fee | $4,250 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $3,400 |
| AstraZeneca UK Limited Jun 15, 2025 | Consulting Fee | $1,370 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 3, 2025 | Consulting Fee Nubeqa · Oncology | $18,000 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 3, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Nashville, TN · in-kind | $865 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 3, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Nashville, TN · in-kind | $80.55 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 3, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Nashville, TN · in-kind | $29.90 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 2, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Nashville, TN · in-kind | $394 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 2, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Nashville, TN · in-kind | $197 |
| Bayer HealthCare Pharmaceuticals Inc. May 23, 2025 | Consulting Fee Nubeqa · Oncology | $900 |
| Pfizer Inc. May 21, 2025 | Consulting Fee | $1,095 |
| Bayer HealthCare Pharmaceuticals Inc. May 20, 2025 | Consulting Fee | $900 |
| Pfizer Inc. May 15, 2025 | Consulting Fee XTANDI · ONCOLOGY | $17,420 |
| AstraZeneca UK Limited May 15, 2025 | Consulting Fee | $2,055 |
| AstraZeneca UK Limited May 15, 2025 | Consulting Fee | $2,055 |
| AstraZeneca Pharmaceuticals LP May 6, 2025 | Consulting Fee | $902 |
| Bayer HealthCare Pharmaceuticals Inc. Apr 28, 2025 | Consulting Fee | $2,700 |
| AstraZeneca UK Limited Apr 14, 2025 | Consulting Fee Truqap · Oncology | $685 |
| AstraZeneca Pharmaceuticals LP Apr 8, 2025 | Consulting Fee Truqap · Oncology Company’s descriptionResearch Related Service | $2,460 |
| AstraZeneca Pharmaceuticals LP Apr 3, 2025 | Consulting Fee Truqap · Oncology Company’s descriptionResearch Related Service | $2,050 |
| Novartis Pharmaceuticals Corporation Mar 25, 2025 | Consulting Fee PLUVICTO · Oncology | $2,550 |
| AstraZeneca UK Limited Mar 15, 2025 | Consulting Fee | $1,370 |
| Merck Sharp & Dohme LLC Mar 10, 2025 | Travel and Lodging travel to Dallas, TX Company’s descriptionProvided as part of a research engagement. | $300 |
| AstraZeneca UK Limited Mar 5, 2025 | Consulting Fee LYNPARZA · Oncology | $685 |
| Novartis Pharmaceuticals Corporation Jan 27, 2025 | Consulting Fee PLUVICTO · Oncology | $1,700 |
| Bayer HealthCare Pharmaceuticals Inc. Jan 16, 2025 | Consulting Fee Nubeqa · Oncology | $1,800 |
| AstraZeneca UK Limited Jan 15, 2025 | Consulting Fee | $1,028 |
| AstraZeneca UK Limited Jan 15, 2025 | Consulting Fee | $1,028 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Travel and Lodging travel to DALLAS, TX Company’s descriptionProvided as part of a research engagement. | $160 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee XTANDI · ONCOLOGY | $17,520 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $2,907,763 in research payments for these studies, mostly to the institutions running them.
- A prospective observational study to aSSEss the rapidly changing TherapY landscape for Renal Cell Carcinoma (ODYSSEY RCC)
Exelixis Inc. - International Registry for Men with Advanced Prostate Cancer
Novartis Pharmaceuticals Corporation - Outcomes Database to prospectivelY aSSEss changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC)
E.r. Squibb & Sons, L.l.c. - Trimodality Approach to Unfavorable Localized Prostate Cancer: a prospective trial of Neoadjuvant Pembrolizumab, ADT, and Prostate SBRT followed by Radical Prostatectomy (TALON)
Merck Sharp & Dohme LLC - A Phase II open label Multi Center study of Apalutamide Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate resistant prostate cancer
Janssen Research & Development, LLC - A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Exelixis Inc. - A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer
Novartis Pharmaceuticals Corporation - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensiti…
AstraZeneca Pharmaceuticals LP - A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration Resistant Prostate Cancer and DNA Repair Anomalies
Janssen Research & Development, LLC - An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.